Pharma Group Pans FDA Guidance On Off-Label Info Sharing

Law360, New York (April 3, 2012, 8:06 PM EDT) -- A drug industry group blasted the U.S. Food and Drug Administration's draft guidance on how companies can respond to unsolicited questions about off-label uses, contending in public comments last week that the guidance would impede manufacturers' ability to communicate with consumers.

The FDA had set a March 29 deadline for stakeholders to comment on the long-awaited draft guidance, which the drug and device industry had been hoping would, among other things, provide guidelines on how they could respond to consumer queries on Facebook and other websites....
To view the full article, register now.